EMA401

Item no.	TMO-T4431-5mg
Manufacturer	TargetMol
CASRN	1316755-16-4
Amount	5mg
Category	Reagents & Chemicals Molecules
Type	Molecules
Specific against	other
Purity	0,98
Citations	1.Rice A S C, Dworkin R H, McCarthy T D, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 Clinicalal trial[J]. The Lancet, 2014, 383(9929): 1637-1647.
Smiles	COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1
ECLASS 5.1	32169090
ECLASS 6.1	32169090
ECLASS 8.0	32169090
ECLASS 9.0	32169090
ECLASS 10.0.1	32169090
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	RAAS, PD-126055 , EMA401
Available
Short Description	Olodanrigan (EMA401), a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. EMA401 blocks p38, p42/p44 mitogen-activated protein kinase (MAPK) activation, neurite outgrowth in adult rat DRG neurons, and sensitization of adult rat and human DRG neurons induced by AngII. It inhibits capsaicin responses in cultured hDRG neurons.
Shipping	cool pack
Storage	-20°
Target names or alias	PD-126055 , EMA401
Molecular Weight	507, 58
Pathway	Endocrinology/Hormones
Target	RAAS

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5mg

available

Delivery expected until 8/9/2024

Express Delivery: Save 4 days

Compare

Add to wishlist

Recommend by mail